{"id":"ne3107","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NE3107 targets the 18 kDa translocator protein (TSPO), which is upregulated in activated microglia and astrocytes during neuroinflammatory conditions. By inhibiting TSPO, the drug reduces mitochondrial dysfunction and neuroinflammatory signaling, thereby decreasing oxidative stress and neuronal damage. This mechanism is intended to slow neurodegeneration in conditions characterized by chronic neuroinflammation.","oneSentence":"NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:47.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"},{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT06847191","phase":"PHASE2","title":"NE3107 in Adults With Neurological Symptoms of Long COVID","status":"RECRUITING","sponsor":"BioVie Inc.","startDate":"2025-04-29","conditions":"Long COVID","enrollment":208},{"nctId":"NCT05970575","phase":"PHASE2","title":"Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury","status":"TERMINATED","sponsor":"Neurological Associates of West Los Angeles","startDate":"2023-12-21","conditions":"Traumatic Brain Injury","enrollment":4},{"nctId":"NCT06757010","phase":"PHASE2","title":"A Study of NE3107 in Early Parkinson's","status":"RECRUITING","sponsor":"BioVie Inc.","startDate":"2025-03-26","conditions":"Parkinsons Disease (PD)","enrollment":60},{"nctId":"NCT05227820","phase":"PHASE2","title":"Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia","status":"COMPLETED","sponsor":"Neurological Associates of West Los Angeles","startDate":"2022-01-19","conditions":"Alzheimer Disease","enrollment":23},{"nctId":"NCT04669028","phase":"PHASE3","title":"A Phase 3 Study of NE3107 in Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2021-08-05","conditions":"Alzheimer Disease","enrollment":439},{"nctId":"NCT05083260","phase":"PHASE1, PHASE2","title":"NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bezisterim"],"phase":"phase_3","status":"active","brandName":"NE3107","genericName":"NE3107","companyName":"BioVie Inc.","companyId":"biovie-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system. Used for Alzheimer's disease, Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}